Clinical trials: Rosacea, Papulopustular
Papulopustular Rosacea
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes.
- Trial name
- NCT05150587
- Testing
- Rifaximin
- Where
- 38 sites in United States
- Volunteers
- 216 people
- Sponsor
- Alfasigma S.p.A.
Rosacea
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular…
- Trial name
- NCT01308619
- Testing
- Doxycycline
- Where
- 10 sites in United States
- Volunteers
- 170 people
- Sponsor
- Galderma R&D
Rosacea
Effect of CD07805/47 Gel in Rosacea Flushing
Phase 2a study to assess the efficacy and safety of CD07805/47 0.5% gel in the prevention of the flush of rosacea.
- Trial name
- NCT02300129
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
To assess the safety of S5G4T-1 when applied once daily for up to 40 weeks in participants with papulopustular rosacea who completed either Study SGT-54-01 (NCT03448939) or Study SGT-54-02 (NCT03564119).
- Trial name
- NCT03564145
- Testing
- S5G4T-1
- Where
- United States
- Volunteers
- 547 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Rosacea
Azelaic Acid on Demodex Counts in Rosacea
The purpose of this study is to measure the effects of azelaic acid on Demodex folliculorum counts and disease condition via a split face design in approximately twenty patients with mild to moderate rosacea.
- Trial name
- NCT03035955
- Testing
- Azelaic acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University
Papulopustular Rosacea (PPR)
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01493687
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 683 people
- Sponsor
- Galderma R&D
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Open Label Pilot Study of Apremilast in Treatment of Rosacea
Rosacea is a chronic skin disorder with the signs and symptoms of facial flushing, persistent redness, small visible spider-like veins, papules (inflamed red bumps under the skin) and pustules.
- Trial name
- NCT01045551
- Testing
- Apremilast
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Julian M. Mackay-Wiggan
Papulopustular Rosacea
An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema
This study is designed to investigate whether topical application of a cromolyn sodium solution is able to decrease the facial redness seen in patients with papulopustular rosacea. Previous work in the lab of Dr.
- Trial name
- NCT01933464
- Testing
- Cromolyn Sodium, Normal Saline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego
Papulopustular Rosacea
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01494467
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 688 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
- Trial name
- NCT03564119
- Testing
- S5G4T-1, S5G4T-2
- Where
- United States
- Volunteers
- 372 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Papulopustular Rosacea
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
The primary objective is to show that open-label extended treatment with FMX103 1.5%, for up to an additional 40 weeks, is safe and well tolerated.
- Trial name
- NCT03276936
- Testing
- FMX103 1.5%
- Where
- 79 sites in United States
- Volunteers
- 504 people
- Sponsor
- Vyne Therapeutics Inc.
Acne Rosacea
Effects of PRK 124 Lotion in Acne Rosacea
The purpose of this open-label study is to determine the tolerance and efficacy of twice-daily application of PRK 124 (Pyratine-6)(0.125%) moisturizing lotion for improving the signs and symptoms of mild to moderate facial…
- Trial name
- NCT00580723
- Testing
- PRK 124
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, Irvine
Papulopustular Rosacea
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
The purpose of this study is to assess the safety and efficacy of azelaic acid (AzA) foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea compared to its vehicle.
- Trial name
- NCT01555463
- Testing
- Azelaic acid foam, 15% (BAY39-6251), Vehicle foam
- Where
- 49 sites in United States
- Volunteers
- 961 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
This exploratory study is being performed to determine whether a new form formulation of azelaic acid 15% is effective in the treatment of papulopustular rosecea.
- Trial name
- NCT00617903
- Testing
- Azelaic acid, Vehicle foam
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea
Subjects with moderate papulopustular rosacea will be treated either with azelaic acid 15% gel topically plus an anti-inflammatory dose of doxycyline (40mg) daily or with metronidazole 1% gel topically once daily plus an…
- Trial name
- NCT00855595
- Testing
- Azelaic acid (Finacea, BAY39-6251), Metronidazole (Metrogel), Doxycycline (Oracea)
- Where
- 17 sites in United States
- Volunteers
- 207 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea
This study will investigate the safety and efficacy of a new formulation of an existing medication for the treatment of papulopustular rosacea. The study will test the active ingredient plus foam against foam alone.
- Trial name
- NCT01025635
- Testing
- Azelaic acid foam 15%, Vehicle foam
- Where
- 20 sites in United States
- Volunteers
- 401 people
- Sponsor
- LEO Pharma
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
A single center prospective, randomized, controlled split face study comparing a 532nm KTP laser with a 595nm PDL for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea.
- Trial name
- NCT02268474
- Testing
- 532nm KTP Laser vs 595nm Pulse Dye Laser
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Papulopustular Rosacea
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are…
- Trial name
- MVOR-1 (NCT05296629)
- Testing
- DFD-29, Doxycycline
- Where
- 27 sites in United States
- Volunteers
- 323 people
- Sponsor
- Journey Medical Corporation
Seborrheic Dermatitis, Papulopustular Rosacea
PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
This study is a double-blind, vehicle-controlled clinical trial. The study will take place at Icahn School of Medicine at Mount Sinai.
- Trial name
- NCT06013371
- Testing
- PF-07038124
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Facial Papulopustular Rosacea
A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
- Trial name
- NCT04608500
- Testing
- FMX103 minocycline foam 1.5%, Vehicle foam
- Where
- 46 sites in United States
- Volunteers
- 771 people
- Sponsor
- Vyne Therapeutics Inc.